Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14422MR)

This product GTTS-WQ14422MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000417.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559
UniProt ID P01589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14422MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4058MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ14675MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SCT-400
GTTS-WQ12518MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ1012MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ14396MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ15449MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ4639MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ12329MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MTIG-7192-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW